Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > BUSINESS
BUSINESS
- [Data] Sales of Zeria's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Fuso's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of ASKA's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Chemiphar's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Wakamoto's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Torii’s Mainstay Products in FY2011
June 19, 2012
- Merck of Germany Considers Entry into Japanese Biosimilars Market
June 18, 2012
- Pharmacists Predict Further Use of Mucosta Generics: Survey
June 18, 2012
- Asklep to Establish Subsidiary in Taiwan, Buffing Up CRO Business in Asia
June 15, 2012
- Antiallergic Agent S-555739 Shows Efficacy in Combination Therapy in PIIb Study: Shionogi
June 15, 2012
- Sales of Januvia, Cervarix Exceed 50 Billion Yen in 2 Years since Launch
June 15, 2012
- DPP-4 Inhibitors Surged, RA Treatments Maintained Strong Growth in FY2011
June 15, 2012
- Top 100 Products in FY2011: Pronounced Growth for ARB Combinations with Declining Sales of Monodrugs
June 15, 2012
- Sanofi, Hisamitsu to Form JV for Allergy-Related OTCs, Seen Eyeing Allegra OTC Launch
June 14, 2012
- Janssen Pharmaceutical to Enlarge Plant Expecting 2.7 Times Current Shipping Volume
June 14, 2012
- Astellas to Collaborate with DNDi on Drug Discovery for Tropical Diseases
June 14, 2012
- MTPC to Launch Tenelia in Sept., Expecting to Become a Growth Driver: President Tsuchiya
June 14, 2012
- Midazolam is Most Used Sedative in Terminal Care: Doctor Survey
June 13, 2012
- Japan Vaccine to Develop, Supply All Vaccines Needed in Japan by 2020
June 13, 2012
- Astellas Launches Dificlir in Europe
June 13, 2012
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…